Document:

Exhibit 10.1

Summary of The Medicines Company Board of Directors Compensation 

On
April 17, 2007, the Board of Directors of The Medicines Company (the “Company”)
adopted new terms of compensation for its non-employee directors as described
below.  The new compensation arrangements
became effective on April 18, 2007.

Cash Compensation

The following table describes the cash compensation
for each non-employee director.  The cash
compensation is payable on a quarterly basis.

	
  Type of Fee

  	
   

  	
  Amount

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Annual Retainer

  	
   

  	
  $

  	
  25,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Additional
  Annual Retainer for Lead Director

  	
   

  	
  $

  	
  10,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Attendance for
  each board meeting attended in person

  	
   

  	
  $

  	
  3,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Attendance for
  each board meeting attended by telephone

  	
   

  	
  $

  	
  1,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Additional
  annual retainer for chairman of audit committee

  	
   

  	
  $

  	
  12,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Additional
  annual retainer for chairman of nominating and corporate governance committee

  	
   

  	
  $

  	
  6,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Additional
  annual retainer for chairman of compensation committee

  	
   

  	
  $

  	
  9,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Annual Retainer
  for Committee Members

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Audit Committee

  	
   

  	
  $

  	
  4,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Compensation Committee

  	
   

  	
  $

  	
  3,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Nominating and Corporate Governance Committee

  	
   

  	
  $

  	
  2,000

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Attendance for
  each committee meeting attended in person

  	
   

  	
  $

  	
  1,500

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Attendance for each
  committee meeting attended by telephone

  	
   

  	
  $

  	
  500

  	
   

  

 

In
addition, directors are reimbursed for travel and out-of-pocket expenses in
connection with their attendance at board meetings.

Equity Compensation

Each non-employee director is eligible to receive
stock options and shares of restricted stock under our 2004 plan. The following
table describes the equity compensation for each non-employee director:

	
  Type of Grant

  	
   

  	
  Number of Options

  	
   

  	
  Number of Restricted Shares

  	
   

  	
  Grant Date

  	
   

  	
  Vesting Schedule

  
	
  Initial Option Grant

  	
   

  	
  20,000

  	
   

  	
  N/A

  	
   

  	
  The date the director is initially elected to the
  board

  	
   

  	
  36 equal monthly installments beginning on the date
  one month after the grant date

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Annual Equity Grant

  	
   

  	
  7,500

  	
   

  	
  3,750

  	
   

  	
  The date of the annual meeting of stockholders

  	
   

  	
  Stock options vest 12 equal monthly installments
  beginning on the date one month after the grant date

   

  Restricted stock vests in one installment 12 months
  after the grant date

  

 

These
options have an exercise price equal to the closing price of the Company’s
common stock on the NASDAQ Global Select Market on the date of grant and have a
ten-year term. All vested options will be exercisable at any time prior to the
first anniversary of the date the director ceases to be a director.  In addition to the annual grant of an option to
purchase 7,500 shares of common stock and 3,750 shares of restricted stock, the
lead director receives an annual grant of an option to purchase 5,000 shares of
the Company’s common stock on the date of the Company’s annual meeting of
stockholders.Exhibit 10.2

CONSULTING AGREEMENT

CONSULTING
AGREEMENT (this “Agreement”), dated as of April 6, 2007  by and between THE MEDICINES COMPANY, a
Delaware corporation with its principal place of business located at 8 Campus
Drive, Parsippany, New Jersey 07054 (the “Company”) and HIROAKI SHIGETA, having
an address of 300 N. Swall Drive #252, Beverly Hills, California 90211 (the “Consultant”).

WHEREAS,
the Company desires to obtain the services and advice of the Consultant and the
Consultant desires to render such services and advice to the Company.

NOW,
THEREFORE, in consideration of the premises and the covenants and agreements
contained herein, and for other good and valuable consideration, the parties
agree as follows:

1.             SERVICES

The
Consultant agrees to perform such consulting and advisory services as may be
requested by the Company and as the Company and the Consultant shall agree from
time to time, including, without limitation, assisting with a business
development strategy in the Japanese market for the Company’s product(s) as
well as researching and advising on pharmaceutical product acquisitions and
seeking potential business partners for product acquisitions. The Consultant
shall coordinate such services with either Clive Meanwell or Glenn Sblendorio
by providing a monthly outline of services in advance of planned efforts.

2.             TERM

The term of this Agreement shall commence
on the date first written above and shall continue until December 31, 2007, but
shall include services rendered since January 1, 2007.  Thereafter, this Agreement shall be subject
to renewal for successive periods upon the further written agreement of the
parties.  Either party may terminate this
Agreement upon thirty (30) days written notice to the other party.  In the event of termination, the Consultant
shall be entitled to payment for services performed prior to the effective date
of termination.  Such payments shall
constitute full settlement of any and all claims of the Consultant of every description
against the Company.

3.             COMPENSATION

During the term of this Agreement, the
Company shall pay the Consultant consulting fees in the amount of $437.50 per
hour, up to a maximum of $3,500.00 per day. 
The Company and Consultant agree that the Consultant shall perform the
first 56 hours of Services under the Agreement without charge.  In addition to fees for Services, the Company
will reimburse reasonable, pre-approved out of pocket expenses necessarily
incurred by the Consultant in connection with the performance of his services
hereunder.  The Consultant will invoice
the Company using the form attached hereto as Exhibit A, for consulting fees
and expenses on a monthly basis, and the Company agrees to pay such invoices
within thirty (30) days after receipt thereof. 
Consulting fees for any partial period shall be prorated.

4.             Inventions
and Proprietary Information

4.1           Inventions

(a)           The Consultant will
make full and prompt disclosure to the Company of all inventions, improvements,
discoveries, methods, developments, software and works of authorship relating
to the Company’s business, whether patentable or not, which are created, made,
conceived or reduced to practice by it or under its direction or jointly with
others during the term of this Agreement (all of which are collectively
referred to in this Agreement as “Developments”).

(b)           The Company shall own
and have title to any Developments made during the term of this Agreement.  The Consultant agrees to assign and does
hereby assign to the Company (or any person or entity designated by the Company)
all of the Consultant’s right, title and interest, if any,  in and to all Developments and all related
patents, patent applications, copyrights and copyright applications.

(c)           The Consultant agrees
to cooperate fully with the Company, both during and after the term of this
Agreement, with respect to the procurement, maintenance and enforcement of
copyrights, patents and other intellectual property rights (both in the United
States and foreign countries) relating to Developments.  The Consultant shall, at the Company’s
expense, sign all papers, including, without limitation, copyright
applications, patent applications, declarations, oaths, formal assignments,
assignments of priority rights and powers of attorney, which the Company may
deem necessary or desirable in order to protect its rights and interests in any
Developments.

4.2           Proprietary Information

(a)           The Consultant agrees
that all information, whether or not in writing, of a private, secret or
confidential nature concerning the Company’s products, business, business
relationships or financial affairs (collectively, “Proprietary Information”) is
and shall be the exclusive property of the Company.  By way of illustration, but not limitation,
Proprietary Information may include inventions, products, processes, methods,
techniques, formulas, compositions, compounds, projects, developments, plans,
research data, clinical data, financial data, personnel data, computer
programs, customer and supplier lists and contacts at or knowledge of customers
or prospective customers of the Company. 
The Consultant will not disclose any Proprietary Information to any
person or entity other than employees of the Company or use the same for any
purposes (other than in the performance of its duties as a consultant of the
Company) without written approval by an officer of the Company, either during
or after the term of this Agreement.

(b)           The Consultant agrees
that all files, letters, memoranda, reports, records, data, sketches, drawings,
laboratory notebooks, program listings or other written, photographic or other
tangible material containing Proprietary Information, whether created by the
Consultant or others, which shall come into its custody or possession, shall be
and are the exclusive property of the Company to be used by the Consultant only
in the performance of its duties for the Company.

 2
 

(c)           The Consultant’s
obligations under this Section 4.2 shall not apply to any information that (i)
is generally known to the public at the time of disclosure or becomes generally
known without Consultant violating this Agreement, (ii) is in the Consultant’s
possession at the time of disclosure without Consultant violating this
Agreement, (iii) becomes known to the Consultant through disclosure by sources
other than the Company without such sources violating any confidentiality
obligations to the Company, or (iv) is independently developed by the
Consultant without reference to or reliance upon the Company’s Proprietary
Information.

(d)           Upon termination of
this Agreement or at any other time upon request of the Company, the Consultant
shall promptly deliver to the Company all records, files, memoranda, notes,
designs, data, reports, price lists, customer lists, drawings, plans, computer
programs, software, software documentation, sketches, laboratory and research
notebooks and other documents (and all copies or reproductions of such
materials) containing or relating to Proprietary Information of the
Company.  After such delivery, the
Consultant shall not retain any such materials or copies thereof.

4.3           Remedies

The Consultant acknowledges that any
breach of the provisions of this Section 4 shall result in serious and
irreparable injury to the Company for which the Company cannot be adequately
compensated by monetary damages alone.  The
Consultant agrees, therefore, that, in addition to any other remedy it may
have, the Company shall be entitled to enforce the specific performance of the
Agreement by the Consultant and to seek both temporary and permanent injunctive
relief (to the extent permitted by law). 
The Company may terminate this Agreement, effective immediately upon the
giving of written notice, if the Consultant breaches or threatens to breach any
provision of this Section 4.

5.             INDEPENDENT CONTRACTOR STATUS

The
Consultant shall perform all of its services under this Agreement as an “independent
contractor” and not as an employee or agent of the Company.  The Consultant is not authorized to assume or
create any obligation or responsibility, express or implied, on behalf of, or
in the name of, the Company or to bind the Company in any manner.  The Consultant shall not be entitled to any
benefits, insurance coverage or privileges, including, without limitation,
social security, unemployment, medical or pension benefits, made available to
the employees of the Company.

6.
            NOTICES

All
notices required or permitted under this Agreement shall be in writing and
shall be mailed,
delivered, or faxed and confirmed in writing, addressed to the other
party at the address shown above, or at such other address or addresses as
either party shall designate to the other in accordance with this Section 6, and any such notices and other
communications shall take effect at the time of receipt thereof.

 3
 

7.             ENTIRE AGREEMENT; AMENDMENT

This
Agreement constitutes the entire agreement between the parties and supersedes
all prior agreements and understandings, whether written or oral, relating to
the subject matter of this Agreement. 
This Agreement may be amended only by a written instrument executed by the
Company and the Consultant.

8.             GOVERNING LAW

This
Agreement shall be construed, interpreted and enforced in accordance with the
laws of the State of New Jersey, without regard to principles of conflicts of
laws.

9.             SUCCESSORS AND ASSIGNS

This
Agreement shall be binding upon, and inure to the benefit of, the parties
hereto and their respective successors and assigns, including any corporation
with which, or into which, the Company may be merged or which may succeed to
its assets or business, provided, however, that the obligations of the
Consultant are personal and shall not be assigned by it without the Company’s
express written consent.

IN
WITNESS WHEREOF, the parties have executed this Agreement as of the day and
year set forth above.

	
  

  	
  THE MEDICINES COMPANY

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By: 

  	
  /s/Clive A. Meanwell

  	
   

  
	
   

  	
  Name: Clive A. Meanwell

  
	
   

  	
  Title: Chairman and CEO

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  /s/ Hiroaki Shigeta

  	
   

  
	
   

  	
  HIROAKI SHIGETA

  
					

 

 4
 

EXHIBIT A

INVOICE FOR PROFESSIONAL SERVICES

	
   

  	
  Date of Invoice:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Payee Name:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  Taxpayer I.D./S.S.#

  	
   

  	
   

  

 

	
  Date of 

  Services

  	
   

  	
  Description of Services

  	
   

  	
  Hours 

  Worked

  	
   

  	
  Hourly Rate

  	
   

  	
  Expenses 

  Incurred

  
	
      

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
      

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

	
   

  	
  Total Hours Worked:

  
	
   

  	
  Total Expenses:

  
	
   

  	
  Total Invoice Amount: $

  

 

 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]